Pantoprazole - Hetero 40mg 30 tablets — Made in India — Free Delivery

Product description

Pantoprazole-Hetero gastro-resistant tablets are prescribed for the following indications:

• Treatment of reflux esophagitis associated with gastroesophageal reflux disease (GERD).
• Maintenance of remission of erosive esophagitis.
• Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.

Compound

Active substance: pantoprazole;

1 tablet contains 20 mg or 40 mg pantoprazole (as pantoprazole sodium sesquihydrate);

Excipients: lactose, hydroxypropyl cellulose, calcium stearate, sodium carbonate anhydrous, sodium lauryl sulfate, shell: hypromellose, yellow iron oxide (E 172), propylene glycol, titanium dioxide (E 171), methacrylate copolymer (type A), triethyl citrate 80, polysorbent black ink (S-1-17823).

Contraindications

Hypersensitivity to the active substance, benzimidazole derivatives and preparation components.

Mode of application

Pantoprazole-Hetero, gastroresistant tablets, are swallowed whole, regardless of food intake. Patients who cannot swallow a 40 mg tablet whole are prescribed two 20 mg tablets. Concomitant use of antacids does not affect the absorption of Pantoprazole-Hetero, gastro-resistant tablets.

Application features

Pregnant

Prescribe only when absolutely necessary.

Children

Pantoprazole-Hetero is recommended for the short-term treatment of EE associated with GERD in patients over 5 years of age.

Drivers

Carefully.

Overdose

Experience with patients receiving ultra-high doses of pantoprazole (> 240 mg) is limited. The available overdose data were usually consistent with the known safety profile of pantoprazole. Pantoprazole is not excreted from the body by hemodialysis. In case of overdose, symptomatic and supportive treatment is prescribed.

Side effects

Metabolism and metabolic disorders. Rarely, hyperlipidemia and increased lipid levels (triglycerides, cholesterol), changes in body weight, increased CPK levels, generalized edema.

From the digestive tract. Uncommon Clostridium difficile-associated diarrhea, nausea, vomiting, bloating, constipation, dry mouth, abdominal pain, and discomfort.

Interaction

The simultaneous administration of atazanavir or nelfinavir with proton pump inhibitors is not recommended, since this may decrease the concentration of atazanavir or nelfinavir in the blood plasma, followed by a decrease in their therapeutic effect and the development of resistance.

Storage conditions

Store at a temperature not exceeding 25 ° C in its original packaging, out of the reach of children.

Shelf life is 2 years.